FDA has granted accelerated approval to Yescarta (axicabtagene ciloleucel) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
